JP Morgan analyst Eric Joseph downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Overweight to Underweight.
Citigroup Maintains Neutral on Nu Skin Enterprises, Raises Price Target to $41
Citigroup analyst Chasen Bender maintains Nu Skin Enterprises (NYSE:NUS) with a Neutral and raises the price target from $35 to $41.